VIA Disc NP for Degenerative Disc Disease: Who May Be a Candidate?

Degenerative disc disease (DDD) is a common cause of chronic low back pain that can develop as the spinal discs gradually lose hydration, flexibility, and structural integrity. For some people, these changes lead to persistent discomfort, stiffness, and difficulty with everyday activities. When conservative treatments do not provide enough relief, patients may explore additional options designed to address pain associated with disc degeneration.

VIA Disc NP is an injectable nucleus pulposus allograft product intended for use in certain patients with degenerative disc disease. The treatment is designed to supplement the material within a damaged spinal disc using processed donated human disc tissue. However, it is not appropriate for everyone, and candidacy depends on the source of pain, the degree of disc degeneration, overall spinal health, and previous treatment outcomes.

Understanding how VIA Disc NP works, who may benefit, and what factors affect eligibility can help patients have a more informed discussion with a spine or pain management specialist.

What Is VIA Disc NP for Degenerative Disc Disease?

VIA Disc NP is an allograft derived from donated human nucleus pulposus tissue, the soft, gel-like material inside an intervertebral disc. It is intended to address disc-related pain by introducing processed disc tissue into a degenerated disc.

Healthy spinal discs help absorb forces and allow the spine to move. As discs degenerate, changes in their composition and structure may contribute to reduced cushioning, inflammation, and pain. VIA Disc NP is intended to supplement the nucleus pulposus rather than remove the disc or surgically fuse adjacent vertebrae.

The procedure involves delivering the allograft material into the targeted disc using image guidance. It is generally performed as a minimally invasive, injection-based procedure rather than open spine surgery.

Importantly, an allograft injection is not the same as regenerating a disc or reversing all degenerative changes. The extent of symptom improvement, durability of results, and long-term effects require careful consideration of the available clinical evidence.

How Does VIA Disc NP Work?

VIA Disc NP is designed to introduce processed nucleus pulposus tissue into a disc affected by degeneration. The nucleus pulposus normally helps the disc distribute loads and maintain its structure.

The treatment aims to supplement the disc’s internal material, potentially supporting its mechanical properties and addressing symptoms associated with disc degeneration. Researchers have investigated whether nucleus pulposus allograft treatments can improve pain and physical function in appropriately selected patients.

However, the response to treatment can vary. Disc degeneration involves multiple structural and biological changes, and adding donor tissue does not guarantee that a disc will regain normal function.

A specialist must also determine whether the patient’s symptoms actually originate from the disc being considered for treatment. An abnormal MRI alone does not establish that a particular disc is responsible for back pain.

Who May Be a Candidate for VIA Disc NP?

A potential candidate for VIA Disc NP generally has chronic low back pain that a specialist believes is primarily caused by degeneration within one or more lumbar intervertebral discs. Clinical research has focused on patients with imaging-confirmed disc degeneration, persistent symptoms, and inadequate improvement with nonsurgical care.

Several factors may help determine whether this treatment is worth discussing.

1. Patients With MRI-Confirmed Lumbar Disc Degeneration

Candidates typically have evidence of degeneration in the lumbar spine on magnetic resonance imaging (MRI). Findings may include changes in disc hydration, structure, or height.

However, disc degeneration is common even in people who have no back pain. A specialist must evaluate whether the imaging findings match the patient’s symptoms and physical examination.

2. Patients With Persistent, Disc-Related Low Back Pain

VIA Disc NP has been studied primarily in people with chronic axial low back pain, meaning pain centered in the lower back rather than symptoms predominantly caused by a compressed spinal nerve.

In the RESTORE clinical trial protocol, eligibility criteria include at least six months of axial low back pain and MRI-confirmed lumbar disc degeneration. The study also evaluates the severity of pain and its effect on daily function.

Patients whose main symptoms are shooting leg pain, numbness, weakness, or other signs of nerve compression may require a different treatment approach.

3. Patients Who Have Not Improved With Conservative Treatment

VIA Disc NP may be considered for investigation when conservative approaches have not provided sufficient relief. These approaches may include physical therapy, activity modification, exercise-based rehabilitation, and appropriate pain management.

The current RESTORE study protocol specifies at least three months of unsuccessful conservative care.

A history of persistent symptoms despite appropriate treatment does not automatically establish candidacy. The specialist must determine whether the disc is the likely source of pain and whether the procedure is appropriate for the patient’s overall condition.

4. Patients With Limited Disc Involvement and Suitable Spinal Anatomy

Clinical studies have generally focused on selected patients with degeneration affecting a limited number of lumbar discs. The RESTORE study evaluates treatment at one or two levels, with additional imaging and clinical criteria used to determine eligibility.

More extensive spinal disease, significant instability, certain disc abnormalities, or other conditions that better explain the symptoms may make a patient unsuitable. These factors require individualized assessment rather than a decision based on MRI findings alone.

Who May Not Be a Candidate for VIA Disc NP?

VIA Disc NP is not designed to address every cause of chronic back pain. Patients may be unsuitable if their symptoms primarily result from another spinal condition or if their anatomy falls outside the treatment’s selection criteria.

Potential reasons for exclusion may include:

• Significant spinal instability or certain forms of vertebral slippage.
• A large disc herniation or extrusion that requires a different treatment strategy.
• Pain primarily caused by facet joints, the sacroiliac joints, or vertebral endplates.
• Significant nerve compression accompanied by neurological symptoms.
• Active infection or certain medical conditions that increase procedural risk.
• Previous spine surgery or other treatments that conflict with the applicable study criteria.

These examples reflect factors considered in clinical research, not a universal exclusion list for every patient. The treating specialist must review the applicable criteria and determine whether another treatment would be more appropriate.

How Is VIA Disc NP Different From Other Treatments for Degenerative Disc Disease?

Treatment for degenerative disc disease depends on the underlying cause of pain, symptom severity, and the patient’s overall health. Common approaches include physical therapy, medications when appropriate, targeted injections for selected pain generators, and surgery in specific circumstances.

VIA Disc NP differs from treatments that target spinal nerves or inflammation because it is intended to supplement tissue within the disc itself. It also differs from spinal fusion, which surgically joins adjacent vertebrae, and artificial disc replacement, which replaces a damaged disc with an implant.

Although its minimally invasive approach may be appealing, VIA Disc NP should not be considered a proven replacement for established treatments. Its safety, effectiveness, and long-term outcomes continue to require evaluation through appropriately designed clinical studies.

What Should Patients Know About Safety and Clinical Evidence?

Early feasibility research has reported encouraging findings, but small preliminary studies cannot establish how well a treatment works compared with a sham procedure or other alternatives. A randomized, sham-controlled, multicenter trial has been designed to evaluate VIA Disc NP more rigorously, including pain outcomes at 12 months and follow-up extending to 24 months.

As of October 2026, VIA Disc NP is being evaluated in clinical research, and patients should confirm its current regulatory status and lawful availability with a qualified specialist or the study team. Participation in a clinical trial may involve specific eligibility requirements, informed consent, follow-up visits, and the possibility of receiving a sham procedure.

Patients should also discuss potential risks of an intradiscal procedure, including infection, bleeding, procedural pain, and possible worsening of symptoms. A clinician can explain the risks relevant to the patient’s medical history and the specific protocol being considered.

How Can Patients Find Out if VIA Disc NP Is Right for Them?

Determining whether VIA Disc NP is appropriate begins with a comprehensive evaluation of chronic low back pain. A specialist may review MRI findings, assess pain patterns, perform a physical examination, and discuss previous treatments and their results.

Patients can prepare for the consultation by bringing prior imaging, a list of treatments already attempted, and a description of activities that aggravate or relieve their symptoms. It is also helpful to ask about alternatives, the strength of the current evidence, potential risks, and whether a clinical trial is available.

The bottom line: VIA Disc NP may be relevant to research involving carefully selected patients with chronic, disc-related low back pain and confirmed lumbar disc degeneration. It is not suitable for every patient with degenerative disc disease, and eligibility requires a specialist assessment. Understanding the true source of back pain is essential to choosing an appropriate treatment plan.